This webinar will be hosted live and available on-demand
Thursday, September 19, 2024
11:00 AM - 12:00 PM ET
Scientists have developed numerous monoclonal antibody (mAb)-based therapies for the treatment of ailments, such as cancer, autoimmune disorders, and infectious diseases. To produce these immunotherapeutics, they must undertake a time- and labor-intensive process involving isolating B cells, assessing their antibody production capabilities, and verifying the specificity and affinity of the resultant mAbs.
In this webinar brought to you by Sartorius, Daryl Cole will discuss how novel automated platforms help researchers enhance the efficiency and effectiveness of these workflows to optimally generate B cell-based immunotherapeutics.
Topics to be covered
- How conventional hybridoma technology compares to modern mAb generation methods
- The limitations inherent to the traditional antibody discovery approaches
- The advantages of employing the Sartorius systems for targeted cell isolation, high-throughput screening, and binding property analysis
 | Daryl Cole, PhD |
